Your browser doesn't support javascript.
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
Greenberg, Ross S; Ruddy, Jake A; Boyarsky, Brian J; Werbel, William A; Garonzik-Wang, Jacqueline M; Segev, Dorry L; Imus, Philip H.
  • Greenberg RS; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Ruddy JA; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Boyarsky BJ; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Werbel WA; Department of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Garonzik-Wang JM; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Segev DL; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. dorry@jhmi.edu.
  • Imus PH; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. dorry@jhmi.edu.
BMC Cancer ; 21(1): 1354, 2021 Dec 27.
Article in English | MEDLINE | ID: covidwho-1632816
ABSTRACT

BACKGROUND:

Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021.

RESULTS:

Rates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted.

CONCLUSIONS:

Two-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunization Schedule / COVID-19 / Antibodies, Viral / Multiple Myeloma Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: BMC Cancer Journal subject: Neoplasms Year: 2021 Document Type: Article Affiliation country: S12885-021-09097-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunization Schedule / COVID-19 / Antibodies, Viral / Multiple Myeloma Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: BMC Cancer Journal subject: Neoplasms Year: 2021 Document Type: Article Affiliation country: S12885-021-09097-5